KL-6、SP-A 及SP-D对儿童间质性肺疾病早期诊断及预后的评估价值

doi:10.3969/j.issn.1671-7171.2022.01.002

摘要
图/表
参考文献(12)
相关文章 (15)

全文: PDF (1172 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨血清涎液化糖链抗原(Krebs von den Lungen-6,KL-6)、肺表面活性物质-A(Surfactant protein A,SP-A)及肺表面活性物质-D(Surfactant protein D,SP-D)对儿童间质性肺疾病(Interstitial lung disease,ILD)早期诊断及预后的评估价值。【方法】选取2016年3月至2020年7月本院呼吸内科诊治的ILD患儿35例(ILD组),另外选取同期在本院诊治感染性肺炎患儿40例(肺炎组)以及40名健康体检儿童作为对照组,检测三组血清 KL-6、SP-A、SP-D水平,并分析其对儿童ILD早期诊断及预后评估的价值。【结果】ILD组血清KL-6、SP-A、SP-D水平高于肺炎组和对照组(P<0.01)。ILD患儿血清 KL-6 水平与最大肺活量 (VC_max)、与一秒率(FEV₁/FVC)呈正相关(r_s=0.339,P<0.05),SP-A 水平与25%最大呼气流量(MEF₂₅)呈负相关(r_s=-0.252,P<0.05);SP-D 水平与 VC_max 呈负相关(r_s=-0.214,P<0.05);肺间质病变评分与KL-6、 SP-A、 SP-D呈正相关(r_s=0.542、0.618、0.515,P<0.01)。KL-6、 SP-A、SP-D三者联合诊断ILD的AUC为0.89、敏感性为83.6%、特异性为97.2%、约登指数为0.81,联合检测对ILD的诊断价值显著高于单独检测(P<0.05)。KL-6、SP-A、SP-D为ILD患儿预后的影响因素(P<0.05)。【结论】KL-6、SP-A、SP-D可作为儿童ILD早期诊断、疾病严重程度及预后的评估指标,三者联合应用可提高诊断ILD的准确性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：肺疾病, 间质性, 肺表面活性物质相关蛋白质A/血液, 肺表面活性物质相关蛋白质D/血液, 诊断, 预后, 儿童

Abstract：【Objective】To analysis the value of Krebs von den Lungen-6 (KL-6), lung Surfactant Protein A (SP-A) and lung Surfactant Protein D (SP-D) for the early diagnosis and prognosis assessment of interstitial lung disease (ILD)in children. 【Methods】A total of 35 children with interstitial lung disease (ILD) hospitalized in Department of Respiratory Medicine of Hunan Children's Hospital from March 2016 to July 2020 were selected as the ILD group, while 40 children hospitalized with infectious pneumonia during the same period were selected as the pneumonia group and 40 healthy children volunteers were selected as the control group. Clinical data of children in the three groups were collected to detect pulmonary function indicators of children in the three groups. Kl-6 was detected by chemiluminescent enzyme immunoassay, and SP-A and SP-D were detected by enzyme-linked immunoassay. The value of all three factors in early diagnosis and prognosis evaluation of interstitial pulmonary disease was analyzed. 【Results】The levels of KL-6, SP-A and SP-D in ILD group were higher than those in pneumonia group and control group (P<0.01). The level of serum KL-6 was positively correlated with maximum vital capacity (VC max) and one second rate (FEV₁/FVC) (r_s=0.339, P<0.05), while the level of SP-A was negatively correlated with 25% maximum expiratory flow (MEF25) (r_s=-0.252, P<0.05) and the level of SP-D was negatively correlated with VC max (r_s=-0.214, P<0.05). Pulmonary interstitial lesion score was positively correlated with KL-6, SP-A and SP-D (r_s=0.542、0.618、0.515,P<0.01). The AUC,sensitivity, specificity and Youden index of KL-6, SP-A and SP-D combined detection were 0.89, 83.6%, 97.2% and 0.81, respectively, indicating that the combined detection of three parameteers was better than the single detection in the diagnosis of ILD. KL-6, SP-A and SP-D were the influencing factors for the prognosis of ILD children(P<0.05). 【Conclusion】KL-6, SP-A and SP-D can be used as indicators of early diagnosis, disease severity and prognosis of interstitial lung disease in children, and their combined detection application can improve the diagnostic accuracy.

Key words： Lung Diseases, Interstitial Pulmonary Surfactant-Associated Protein A/BL Pulmonary Surfactant-Associated Protein D/BL Diagnosis Prognosis Child

收稿日期: 2021-09-01

中图分类号:

R725.63

基金资助:湖南省卫生健康委员会科研计划课题项目(编号:20200609)

通讯作者: **E-mail:hnchenyanping@163.com

引用本文:

段效军, 张喜, 安照辉, 孟燕妮, 李林瑞, 陈艳萍. KL-6、SP-A 及SP-D对儿童间质性肺疾病早期诊断及预后的评估价值[J]. 医学临床研究, 2022, 39(1): 5-8.
DUAN Xiao-jun, ZHANG Xi, AN Zhao-hui, et al. Value of KL-6, SP-A and SP-D in Early Diagnosis and Prognosis Assessment of Interstitial Lung Disease in Children. JOURNAL OF CLINICAL RESEARCH, 2022, 39(1): 5-8.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.01.002 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I1/5

[1] GEORGE P M, SPAGNOLO P,KREUTER M,et al.Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities[J].Lancet Respir Med,2020,8(9):925-934.
[2] MONTESI S B, FISHER J H, MARTINEZ F J, et al. Update in interstitial lung disease 2019[J].Am J Respir Crit Care Med,2020, 202(4):500-507.
[3] 王冉冉,朱剑,张江林. KL-6 在间质性肺疾病诊治中的研究进展[J].解放军医学杂志, 2017, 42(4): 354-357.
[4] SASAKI H, HARA Y, TAGURI M,et al.Serum surfactant protein A as a surrogate biomarker of a negative heart sign among patients with interstitial lung disease[J].Nagoya J Med Sci,2020,82(3):499-508.
[5] 中华医学会儿科学分会呼吸学组全国儿童弥漫性肺实质疾病/肺间质疾病协作组.儿童肺间质疾病诊断程序专家共识[J].中华儿科杂志, 2013, 51(2): 101-102.
[6] 中华医学会儿科学会分会呼吸学组, 临床儿科杂志编辑委员会.儿童肺功能检测及评估专家共识[J].临床儿科杂志,2014,32(2): 104-114.
[7] FISCHER A, ANTONIOU K M, BROWN K K, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features[J].Eur Respir J,2015, 46(4): 976-987.
[8] CHIBA H, OTSUKA M, TAKAHASHI H. Significance of molecular biomarkers in idiopathic pulmonary fifibrosis: A mini review[J].Respir Investig,2018,56(5):384-391.
[9] OHSHIMO S,YOKOYAMA A,HATTORI N,et al. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts[J].Biochem Biophys Res Commun,2005,338(4):1845-1852.
[10] XU L, YAN D R, ZHU S L, et al.KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation[J].Eur Rev Med Pharmacol Sci,2013,17(22):3073-3077.
[11] WANG K, JU Q, CAO J,et al.Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J].Medicine (Baltimore),2017,96(23):e7083.
[12] IKEDA K, SHIRATORI M, CHIBA H, et al. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fifibrosis treated with pirfenidone[J].Respir Med,2017,131:184-191.